C5,C6-disubstituted 1H-indole-2-carboxamides:: Synthesis and cytotoxic activity in the human non-small lung cancer cell line NSCLC-N16-L16

被引:5
|
作者
Tsotinis, A
Gerasimopoulou, M
Vlachou, M
Moreau, D
Roussakis, C
机构
[1] Univ Athens, Fac Pharm, Dept Pharmaceut Chem, Athens 15771, Greece
[2] Fac Pharm, Lab Pharmacol Marine, ISOMER, Nantes, France
关键词
disubstituted; 1H-indole-2-carboxamides; synthesis; cytotoxicity;
D O I
10.2174/157018006775240980
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A facile synthesis of the disubstituted 1H-indole-2-carboxamides (6a-h) is described. Readily available 4-benzyloxy-3-methoxybenzaldehyde is converted to the parent acid (12) by nucleophilic attack of the azido-ester (9) and cyclization of the propenoic methyl ester (10). The target compounds (6a-d) were obtained by amidation of (12) with the appropriate primary amine. The new 6-hydroxy analogs (6e-h) were prepared by benzyl deprotection of (6a-d). The cytotoxicity of the new molecules was evaluated in the human non-small lung cancer cell line NSCLC-N16-L16 in vitro. One compound (6d) showed satisfactory activity (IC50 = 13.9 mu M) worthy of further study. It is noteworthy that few agents are clinically effective against human non-small lung cancer, and thus there is a need for novel agents for use in this disease.
引用
收藏
页码:14 / 16
页数:3
相关论文
共 25 条
  • [1] SAKK 16/14-Perioperative Anti-PD-L1 Antibody Durvalumab in Patients with Stage IIIA(N2) Non-Small Cell Lung Cancer (NSCLC)
    Rothschild, S.
    Zippelius, A.
    Savic, S.
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2149 - S2149
  • [2] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neo-adjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)
    Rothschild, S. I.
    Zippelius, A.
    Eboulet, E. I.
    Savic, S.
    Betticher, D.
    Bettini, A.
    Fruh, M.
    Jorger, M.
    Britschgi, C.
    Peters, S.
    Mark, M.
    Ochsenbein, A. F.
    Janthur, W. -D.
    Waibel, C.
    Mach, N.
    Gonzalez, M.
    Frosch, P.
    Goddar, G.
    Rusterholz, C.
    Pless, M.
    SWISS MEDICAL WEEKLY, 2020, : 3S - 3S
  • [3] L-(1-11C)tyrosine (TYR) PET for protein synthesis rate (PSR) assessment of small cell and non-small cell lung cancer (SCLC, NSCLC) before and after therapy.
    Pieterman, RM
    Appel, M
    Pruim, J
    Willemsen, AT
    Koëter, GH
    Groen, HJ
    Vaalburg, W
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 273P - 274P
  • [4] Phase 1-2 dose-ranging trial of TLK286 (TELCYTA) and Cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC)
    Papadimitrakopoulou, V
    Edelman, M
    Zinner, R
    Blumenschein, G
    Jones, S
    Willcutt, N
    Keck, J
    Brown, G
    Burris, H
    LUNG CANCER, 2005, 49 : S262 - S263
  • [5] Simple 2(5H)-furanone derivatives with selective cytotoxicity towards non-small cell lung cancer cell line A549-Synthesis, structure-activity relationship and biological evaluation
    Byczek-Wyrostek, Anna
    Kitel, Radoslaw
    Rumak, Klaudia
    Skonieczna, Magdalena
    Kasprzycka, Anna
    Walczak, Krzysztof
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 150 : 687 - 697
  • [6] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) - A multicenter single-arm phase II trial
    Rothschild, S. I.
    Zippelius, A.
    Eboulet, E. I.
    Prince, S. Savic
    Betticher, D.
    Bettini, A.
    Fruh, M.
    Joerger, M.
    Britschgi, C.
    Peters, S.
    Mark, M. T.
    Ochsenbein, A. F.
    Janthur, W-D.
    Waibel, C.
    Mach, N.
    Gonzalez, M.
    Froesch, P. R.
    Godar, G.
    Rusterholz, C.
    Pless, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S803 - S804
  • [7] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial.
    Rothschild, Sacha
    Zippelius, Alfred
    Eboulet, Eric, I
    Savic, Spasenija
    Betticher, Daniel C.
    Bettini, Adrienne
    Frueh, Martin
    Joerger, Markus
    Britschgi, Christian
    Peters, Solange
    Mark, Michael Thomas
    Ochsenbein, Adrian
    Janthur, Wolf Dieter
    Waibel, Christine
    Mach, Nicolas
    Gonzalez, Michel
    Froesch, Patrizia
    Godar, Gilles
    Rusterholz, Corinne
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Transactivation of hsp70-1/2 human non-small cell lung in geldanamycin-treated cancer H460 cells:: Involvement of intracellular calcium and protein kinase C
    Shu, CW
    Cheng, NL
    Chang, WM
    Tseng, TL
    Lai, YK
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 94 (06) : 1199 - 1209
  • [9] Inhibition of Na plus /H plus exchanger (NHE) 7 by 5-(N-ethyl-N-isopropyl)-Amiloride displays anti-cancer activity in non-small cell lung cancer by disrupting cancer stem cell activity and downregulating PD-L1 expression
    Wang, Bing -Yen
    Shen, Huan-Ting
    Lee, Yu-Ling
    Chien, Peng-Ju
    Chang, Wen -Wei
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (10): : 4721 - +
  • [10] Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC)
    Zhao, Long
    Liu, Jinjun
    Wang, Huoqiang
    Shi, Jingyun
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1119):